Ipsen’s purpose in oncology
We are shaping the future of cancer care. For more than three decades, we have advanced bold science and pioneered novel treatments for complex tumors and rare cancers.
Redefining standards of care where patients have few or no options, we deliver transformational therapies across genitourinary, gastrointestinal, rare & hematological cancers. We continue to pursue the unanswered questions, working with healthcare systems and communities to optimize care for patients.
Through biomarker-driven approaches, we are expanding our pipeline with first- and best-in-class modalities to develop the next breakthrough treatment, delivering the right treatments to the right patients.
How Ipsen drives science with purpose in oncology
Ipsen’s science in ADCs
Achieving balance with precision
We are focused on maximizing the potential of the three key components of ADCs in solid tumors – the monoclonal antibody, the cytotoxic agent, and the linker.
Targeting tumor-specific antigens with innovative linker-payload designs and evaluating assets with a optimized DAR (drug-antibody ratio), we aim to achieve strong anti-tumor activity across a number of solid tumors, while maintaining promising safety profiles.
Ipsen’s science in MAPK
We follow the science to better target the tumor
Our expert teams are exploring ways to more effectively block the MAPK pathway at multiple points, addressing challenges like pathway reactivation and resistance.
We aim to unlock the diversity of the MAPK pathway by targeting different proteins, across multiple solid tumor types, using biomarker-driven mutation identification to find the patients who will benefit most.
Through data-backed decision making and an unwavering commitment to treating some of the most challenging cancers, we aim to develop targeted therapies that improve patient outcomes.
Ipsen’s science in TCAs
Advancing precision immune activation
Harnessing the immune system to fight cancer requires both precision and control. At Ipsen, we are advancing T cell activators (TCAs) designed to elevate the body’s natural defenses, enhancing the ability of T cells to recognize and destroy cancer cells.
Focusing on precision antibody binding and selective activation of the most effective T cell subsets, we are working to generate potent and controlled anti-cancer immune responses. Through this deliberate approach, our aim is to redefine immunological therapies for people facing some of the most difficult-to-treat cancers.
Ipsen’s science in TCEs
Binding science to cancer
T cell engagers (TCEs) act as a bridge between the immune system and the tumor. At Ipsen, we are developing the next generation of TCEs, built on precision, selectivity and innovative design.
Engineered to selectively activate T cells while precisely binding tumor targets, our TCEs are designed to bind science to cancer, delivering deeper, durable, and controlled immune responses in solid tumors. Through this science-led approach, we aim to advance more effective immunotherapies for people facing cancers where treatment options remain limited.
Ipsen’s science in hematology
Transforming blood cancer through precision science
At Ipsen, we bring the same scientific rigour that has driven our breakthroughs in oncology to the urgent and complex challenges of haematology. Our focus is deliberate and directed at the most aggressive and underserved haematological malignancies, where the need is greatest and the science most demanding.
Our ambition is to reshape the future of hemato-oncology. We are advancing precision approaches that directly target the molecular drivers of disease—while also exploring how the immune system can be mobilised to fight back. This dual focus allows us to pursue therapies that are not only innovative, but potentially transformative.
Ipsen is building a specialised and globally relevant haematology pipeline—designed to deliver what patients and healthcare teams need most: speed, clarity, and solutions that challenge the status quo.
Ipsen’s companion diagnostic strategy
Advancing Ipsen’s precision medicine through companion diagnostics
Companion diagnostics are central to our precision approach in oncology. These medical tests evaluate specific biomarkers in the body, such as genetic changes or protein levels, to guide how a medicine is developed and identify which patients are most likely to benefit.
We design each of our development programs with companion diagnostics in mind. Depending on the therapy’s stage of development, we partner with diagnostic companies to co-develop new assays or integrate diagnostics already in progress. This approach enables smarter trials, higher success rates, and more targeted treatments.
By combining our internal expertise with strong collaborations, we integrate therapeutic and diagnostic development to accelerate the delivery of precision medicines, helping patients access the right treatment, with the right test, at the right time.
Meet the team
Discover the people driving R&D at Ipsen, advancing science with purpose all the way from discovery to patient impact.
Advancing Science with Purpose
We’re advancing medicines in oncology, rare diseases and neuroscience through science-led innovation. Explore our Rare Disease area to see how we’re transforming innovation into medicine.